RxDoctor Payments Data

Surinder Sandhu, MD

Cardiovascular Disease · Fresno, CANPI 1669497137

Payments from drug & device makers

$7,841in general payments, 2019–2025

Across 170 payments — averaging $46.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$371
  • AstraZeneca$306
  • Amgen$268
  • Novartis$169
  • Abbott$132
  • plus $704 from 20 others

What the payments were for

  • Travel & lodging$4,68560%
  • Food & beverage$3,09639%
  • Education$601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,841 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$259,282
Medicare patients
873
Services billed
2,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$415,576
Repatha SureclickEvolocumab115$124,813
EntrestoSacubitril/Valsartan26$38,918
XareltoRivaroxaban19$28,960
FarxigaDapagliflozin Propanediol16$22,111
VascepaIcosapent Ethyl27$17,064
Rosuvastatin Calcium628$13,975
BrilintaTicagrelor14$9,969
Metoprolol Succinate484$7,941
Icosapent Ethyl23$7,799
Ezetimibe101$4,455
Ranolazine ErRanolazine57$4,310
Felodipine ErFelodipine117$3,919
Losartan Potassium279$2,841
Nitroglycerin116$2,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$415,576291 claims
NovartisEntresto$169$38,91826 claims
AstraZenecaFarxiga, Brilinta$306$32,07930 claims
Johnson & JohnsonXarelto$13$28,96019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →